Tags : Charles River

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery

Shots: The collaboration provides Charles River’s client access to Fios Genomics’ expertise in bioinformatics, statistics and biology, assisting the sourcing and analysis datasets associated with the drug development including microarrays, NGS, proteomics, metabolomics, epigenetics and associated meta-data The agreement merges Fios’ biologically-relevant insights with Charles River’s drug discovery and development platform and the scientific expertise […]Read More

Takeda Collaborates with Charles River to Identify and Develop Preclinical

Shots: Charles River to receive up front, up to $50M as development milestones/ program, up to $120M as commercial milestones and royalties on net sales of the developed products. Takeda to launch multiple integrated programs targeting its four core therapeutic areas (oncology, gastroenterology, neuroscience, and rare disease) and will get an option to advance the […]Read More

Charles River to Acquire HemaCare Corporation for $380M

Shots: Charles River to acquire HemaCare in all cash transactions at $25.40 /share, making a total deal value $380M with a premium of 33% to HemaCare’s volume-weighted average stock price over the last 60 trading days. The transaction is expected to be completed in Q1’20 The focus of the acquisition is to expand Charles River’s […]Read More